

Virbagen canis SHA/L Lyophilisat und Suspension zur Herstellung einer Injektionssuspension für Hunde

Authorised

- Canine distemper virus, strain Lederle VR128, Live
- Canine adenovirus 2, strain Manhattan, Live
- Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
- Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated

Product identification

Medicine name:

Virbagen canis SHA/L Lyophilisat und Suspension zur Herstellung einer Injektionssuspension für Hunde

Active substance:

Canine distemper virus, strain Lederle VR128, Live

Canine adenovirus 2, strain Manhattan, Live

Leptospira interrogans, serovar Canicola, strain 601903, Inactivated

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine distemper virus, strain Lederle VR128, Live
1000.00 50% cell culture infectious dose / 1.00 Dose

Canine adenovirus 2, strain Manhattan, Live
10000.00 50% cell culture infectious dose / 1.00 Dose

Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
4350.00 enzyme-linked immunosorbent assay unit / 1.00 Dose

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
4250.00 enzyme-linked immunosorbent assay unit / 1.00 Dose

Pharmaceutical form:

Lyophilisate and suspension for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AI01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Germany

Available in:

Germany

Package description:

Available only in [German](#)

Available only in [German](#)

Available only in [German](#)

Available only in [German](#)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:

Virbac Tierarzneimittel GmbH

Marketing authorisation date:

21/12/2005

Manufacturing sites for batch release:

Virbac

Responsible authority:

Paul-Ehrlich-Institut

Authorisation number:

154a/80

Date of authorisation status change:

11/11/2010

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.